生化基因 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 Commission File Number 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) 33-0112644(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization) 225 Binney Street, Cambridge, MA 02142(617)679-2000 (Address, including zip code, and telephone number, includingarea code, of registrant’s principal executive offices) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) ofthe Securities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant wasrequired to file such reports), and (2)has been subject to such filing requirements for the past 90days:YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for suchshorter period that the registrant was required to submit such files):YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer,a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “acceleratedfiler,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act: Accelerated filer☐Smallerreportingcompany☐Emerging growth company☐ Large accelerated filerNon-acceleratedfiler☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extendedtransition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a)of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the ExchangeAct).Yes☐No The number of shares of the issuer’s Common Stock, $0.0005par value, outstanding as of April27, 2026, was147,637,117 shares. BIOGEN INC.FORM10-Q — Quarterly ReportFor the Quarterly Period Ended March 31, 2026 TABLE OF CONTENTS PARTI—FINANCIAL INFORMATION Item 1.Financial Statements (unaudited)Condensed Consolidated Statements of Income— For the Three Months Ended March 31, 2026 and 20258Condensed Consolidated Statements of Comprehensive Income — For the Three Months Ended March 31,2026 and 20259Condensed Consolidated Balance Sheets— As of March 31, 2026 and December31, 202510Condensed Consolidated Statements of Cash Flow— For the Three Months Ended March 31, 2026 and202511Condensed Consolidated Statements of Equity — For the Three Months Ended March 31, 2026 and 202512Notes to Condensed Consolidated Financial Statements13Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations43Item 3.Quantitative and Qualitative Disclosures About Market Risk67Item 4.Controls and Procedures69 PARTII—OTHER INFORMATION Item 1.Legal Proceedings70Item1A.Risk Factors70Item 2.Unregistered Sales of Equity Securities and Use of Proceeds86Item 5.Other Information86Item 6.Exhibits87Signatures88 NOTE REGARDING FORWARD-LOOKING STATEMENTS This report contains forward-looking statements that are being made pursuant to the provisions of the Private SecuritiesLitigation Reform Act of 1995 (the PSLRA) with the intention of obtaining the benefits of the “Safe Harbor” provisions of thePSLRA. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” "assume,"“believe,” “contemplate,” “continue," "could," “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,”“objective,” "outlook," “plan,” “possible,” "potential," “predict,” “project,” "seek," “should,” “target,” “will,” “would” or thenegative of these words or other words and terms of similar meaning. Given their forward-looking nature, thesestatements involve substantial risks and uncertainties and may be based on inaccurate assumptions. This report includes,among others, forward-looking statements regarding: •our expected financial and operating performance; •our long-term strategy and supporting business plans, including our product pipeline;•our expectations about continued growth through acquisitions and key collaborative relationships and fundingarrangements;•our belief that our long-term competitive position depends upon our success in discovering and developing innovative,cost-effective products that serve unmet medical needs, along with our ability to manufacture products efficiently andto launch and market them effectively in a highly competitive environment;•our ability to obtain and maintain adequate coverage, pricing and reimbursement from third-party pay